Qu Biologics Inc.: federal grants and contributions: 14 agreements; $9.2M value; 1 departments; 3 programs.
Assay record ASY-CA-0SGPKTM1DL · Cite as: Assay Systems, “Qu Biologics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/qu-biologics-inc/
This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The Project will support development of intellectual property capacity within the Firm.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.